Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00404521 | A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors | terminated | Phase 1 | 56 | PharmaMarINDUSTRY | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00884845 | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 35 | PharmaMarINDUSTRY | 2 | Mar 26, 2014 | clinicaltrials |
| NCT01184807 |
| Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 51 |
| Otsuka Beijing Research InstituteINDUSTRY |
| 1 |
| Mar 26, 2014 |
| clinicaltrials |
| NCT00125827 | Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00942799 | Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors | completed | Phase 1 | 87 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01641575 | A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin | terminated | Phase 1 | 8 | Clovis Oncology, Inc.INDUSTRY | 2 | Mar 11, 2014 | clinicaltrials |
| NCT00601614 | Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Mar 10, 2014 | clinicaltrials |
| NCT00003766 | O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery | completed | Phase 1 | 25 | University of ChicagoOTHER | 1 | Mar 6, 2014 | clinicaltrials |
| NCT01455571 | Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors | completed | Phase 1 | 55 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Feb 26, 2014 | clinicaltrials |
| NCT01058538 | A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | completed | Phase 1 / Phase 2 | 33 | Philogen S.p.A.INDUSTRY | 2 | Feb 25, 2014 | clinicaltrials |
| NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | terminated | Phase 1 / Phase 2 | 29 | Philogen S.p.A.INDUSTRY | 1 | Feb 25, 2014 | clinicaltrials |
| NCT01364844 | Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors | completed | Phase 1 | 42 | Daiichi SankyoINDUSTRY | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00046917 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00112684 | Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00121290 | SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00227513 | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00324480 | Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00348699 | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00357318 | Bevacizumab and Sunitinib in Treating Patients With Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00436579 | Sorafenib in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00462553 | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00622414 | Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00701298 | Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01145456 | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00006095 | Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy | completed | Phase 1 | 20 | Children's Oncology GroupNETWORK | 2 | Feb 21, 2014 | clinicaltrials |
| NCT00006463 | Ecteinascidin 743 in Treating Children With Refractory Solid Tumors | completed | Phase 1 | 13 | Children's Oncology GroupNETWORK | 3 | Feb 21, 2014 | clinicaltrials |
| NCT00070473 | Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors | completed | Phase 1 | 33 | Children's Oncology GroupNETWORK | 2 | Feb 20, 2014 | clinicaltrials |
| NCT01012102 | EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors | completed | Phase 1 | 104 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | Feb 20, 2014 | clinicaltrials |
| NCT00458731 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | completed | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01428141 | A Phase I Study of E7050 in Subjects With Solid Tumors | completed | Phase 1 | 18 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 14, 2014 | clinicaltrials |
| NCT01050985 | A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer | completed | Phase 1 | 47 | Georgetown UniversityOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT00125840 | Clofarabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT01168752 | Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma | completed | Phase 1 | 81 | Debiopharm International SAINDUSTRY | 1 | Feb 3, 2014 | clinicaltrials |
| NCT00391521 | AS703569 Phase I in Patients With Solid Tumours | completed | Phase 1 | 104 | EMD SeronoINDUSTRY | 1 | Jan 30, 2014 | clinicaltrials |
| NCT01273090 | Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma | completed | Phase 1 | 34 | Children's Oncology GroupNETWORK | 2 | Jan 30, 2014 | clinicaltrials |
| NCT00978523 | Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma | completed | Phase 1 | 35 | Arno TherapeuticsINDUSTRY | 2 | Jan 29, 2014 | clinicaltrials |
| NCT01170897 | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00387920 | Sunitinib in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 2 | Jan 28, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT01306630 | A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00827177 | Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 87 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jan 24, 2014 | clinicaltrials |
| NCT00052403 | Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Jan 16, 2014 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00054288 | Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors | completed | Phase 1 | — | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00084708 | Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 53 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00112892 | Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 26, 2014source: clinicaltrials